Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas

Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors and Lymphomas

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00023166

Enrollment

Unknown

Registered

2001-08-27

Start date

2001-05-31

Completion date

2002-05-31

Last updated

2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphomas, Neoplasm, Neoplasm Metastasis

Keywords

Phase I, Open label, Safety/efficacy, Lymphomas, Advanced primary and/or metastatic solid tumors, Neoplasms, Neoplasm metastasis

Brief summary

Studies of PEG-paclitaxel have been terminated

Interventions

DRUGPEG-paclitaxel

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

None - Study has been terminated.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026